Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)

The summary for the Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42): The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease.
Federal Grant Title: Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PA-14-308
Type of Funding: Grant
CFDA Numbers: 93.350
CFDA Descriptions: National Center for Advancing Translational Sciences
Current Application Deadline: Sep 7, 2016
Original Application Deadline: Sep 7, 2016
Posted Date: Aug 4, 2014
Creation Date: Aug 4, 2014
Archive Date: Oct 8, 2016
Total Program Funding:
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following:
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:

1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;

2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;

3. (i) SBIR and STTR. Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR

(ii) SBIR-only. Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR

(iii) SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.

4. Has, including its affiliates, not more than 500 employees.
Link to Full Grant Announcement
http://grants.nih.gov/grants/guide/pa-files/PA-14-308.html
Grant Announcement Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants
Drug Development Collaboratory (UG3/UH3 Clinical Trial Required)
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...
Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...
Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortenin...
Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-...
Limited Competition: Revision Applications to Advance Evidence-Based Research Related to P...
A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for...
Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for E...
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2020 FederalGrants.com